Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 03

410P - Patients treated with pertuzumab followed by T-DM1 for breast cancer in France from 2014 to 2021: A survival analysis of 10,408 patients from the French National Hospital discharge summary database (PMSI)

Date

21 Oct 2023

Session

Poster session 03

Topics

Tumour Site

Breast Cancer

Presenters

Josephine Lemaitre

Citation

Annals of Oncology (2023) 34 (suppl_2): S334-S390. 10.1016/S0923-7534(23)01260-7

Authors

J. Lemaitre1, E. Chazard2, P. Cren3, L. Lebellec4, N. Penel5, C. Cheymol6

Author affiliations

  • 1 Medical Oncology, Centre Oscar Lambret, 59000 - Lille/FR
  • 2 Cerim, CHU Lille - Centre Hospitalier Régional Universitaire de Lille, 59037 - Lille/FR
  • 3 Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 4 Hauts De France, Centre Oscar Lambret, 59020 - Lille/FR
  • 5 Medical Oncology Department, Centre Oscar Lambret, 59020 - Lille/FR
  • 6 Nord, Centre Oscar Lambret, 59020 - Lille/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 410P

Background

Breast cancer represents a major public health issue in which numerous therapeutic advances have been made, particularly for those with HER2 overexpression. The standard of care until mid-2022 has been based on the combination of Trastuzumab - Pertuzumab - Docetaxel in first line, followed by T-DM1 in second line. Limited data are available on survival outcomes of patients receiving these treatments in a real-life setting. We aimed to analyse them in this study.

Methods

We searched the French PMSI (French National Hospital Discharge Summary Database) database and extracted 10,408 patients treated with Pertuzumab between 2014 and 2021, with a C50* code (coding for breast cancer) and with an index stay in a public or private non-profit hospital. We then extracted administrative data, comorbidities, types of metastases and survival. We collected and analyzed the same data for patients receiving T-DM1 after Pertuzumab.

Results

Median survival for patients treated with Pertuzumab was not reached at time of analysis (February 2023). Survival rate at 5 years was 61.9 % (CI95% [60.6, 63.1]). Several risk factors were identified : an intensive care unit stay, age and a code for hydroelectrolytic disorders, metastases (particularly cerebromeningeal, liver, bone, and lung metastases), infection, diabetes, undernutrition and cytopenias. Median survival for patients treated with T-DM1 after Pertuzumab was 2.8 years (CI95% [2.65,2,99]), with a 5-year survival rate of 36.9% (CI95% [34.6 , 39.4]). Risk factors were : a code for liver or cerebromeningeal metastases, undernutrition, and age.

Conclusions

To our knowledge, this is the largest real-life cohort of patients with breast cancer treated with Pertuzumab followed by T-DM1, and our results are consistent with available data, both from the lead CLEOPATRA and EMILIA studies and other retrospective studies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.